Translational potential of a novel osteoclast inhibitor, eliglustat, in myeloma bone disease
<p>Multiple myeloma is a fatal haematological malignancy, in which the majority of patients either present with or develop a destructive and debilitating osteolytic bone disease. The bone disease is characterised by an increase in osteoclastogenesis and by osteoblast suppression. Current trea...
Main Author: | Leng, H |
---|---|
Other Authors: | Simon, K |
Format: | Thesis |
Language: | English |
Published: |
2019
|
Subjects: |
Similar Items
-
Interleukin-32 promotes osteoclast differentiation but not osteoclast activation
by: Mabilleau, G, et al.
Published: (2009) -
Stimulation of osteoclast formation by inflammatory synovial fluid
by: Adamopoulos, I, et al.
Published: (2006) -
Increased osteoclastic activity in acute Charcot's osteoarthropathy: the role of receptor activator of nuclear factor-kappaB ligand
by: Mabilleau, G, et al.
Published: (2008) -
Expression of Receptor Activator of Nuclear – Kappa β Ligand in Patients with Metastatic Bone Disease
by: Magetsari, Rahadyan, et al.
Published: (2022) -
Maintenance therapy in multiple myeloma
by: Jean-Luc Harousseau
Published: (2009-08-01)